LACTOLOGY FOUNDATION

Magaldrate–antiflatulent combinations (ATC A02AF01) are antacid products in which the lactation risk is driven mainly by the aluminum‑rich magaldrate component, while typical antiflatulents (for example simethicone) contribute minimal additional risk in breastfeeding.

Scope and pharmacological profile

ATC class A02AF01 comprises fixed‑dose combinations of magaldrate with antiflatulents and falls within the “antacids with antiflatulents” group.
Magaldrate is an inorganic complex of aluminum and magnesium hydroxides used orally as a local antacid in the management of duodenal and gastric ulcers, reflux esophagitis and dyspeptic symptoms, usually as over‑the‑counter medication.

These combinations are formulated to provide rapid neutralization of gastric acid together with relief of gas‑related symptoms such as flatulence, bloating and abdominal distension.
Antiflatulent components are most often surface‑active agents such as simethicone or related dimethicone derivatives, which reduce surface tension of gas bubbles in the gastrointestinal lumen and facilitate their coalescence and elimination.

Mechanism of action and pharmacokinetics

Magaldrate reacts with gastric hydrochloric acid to form aluminum and magnesium salts, thereby increasing intragastric pH and reducing pepsin activity.
The compound acts locally in the stomach and proximal small intestine, and systemic absorption of intact magaldrate is negligible; instead, small amounts of released aluminum and magnesium ions may be absorbed.

Antiflatulents such as simethicone are physiologically inert silicone polymers that are not absorbed from the gastrointestinal tract to a clinically relevant extent and are excreted unchanged in the feces.
Because of the very low oral bioavailability of simethicone, maternal systemic exposure is minimal and milk transfer is expected to be extremely low.

General toxicology relevant to lactation

Aluminum‑containing antacids, including magaldrate, may theoretically contribute to aluminum exposure in breastfed infants, particularly with high maternal doses or prolonged administration.
Nonetheless, reviews of antacid use during breastfeeding conclude that products based on aluminum and magnesium hydroxides produce low maternal plasma levels and that only very small quantities, if any, reach breast milk in most clinical situations.

In healthy term infants with normal renal function, occasional exposure to low amounts of aluminum and magnesium via breast milk is unlikely to be clinically significant, whereas preterm neonates or infants with renal impairment are more vulnerable to cumulative aluminum toxicity.
Potential toxic manifestations in the infant, if significant exposure occurred, would include gastrointestinal disturbances, altered bone mineralization and neurodevelopmental concerns, although such effects have not been clearly associated with maternal therapeutic antacid use.

Antiflatulents such as simethicone have an excellent safety profile; they are not systemically bioavailable, have no known serious systemic toxicities and are widely used directly in infants for gas and colic.
Consequently, from a toxicological standpoint the antiflatulent component is usually considered of negligible relevance for lactation risk compared with the aluminum‑containing antacid.

Lactation risk assessment (A02AF01)

Expert reviews of antacids and related gastrointestinal medicines consider standard‑dose antacid and simethicone therapies compatible with breastfeeding in most cases, given low maternal absorption and minimal transfer to breast milk.
However, the specific magaldrate–antiflatulent combinations in class A02AF01 must be assessed conservatively, because magaldrate is an aluminum‑rich complex and some sources recommend caution with aluminum‑containing antacids during lactation, especially when safer alternatives exist.

On your page, magaldrate‑containing products are assigned a toxicological lactation category III, indicating that the active substance and/or its metabolites may reach breast milk at concentrations similar to or higher than maternal plasma levels, with a potential for toxic reactions in the newborn.
Under this framework, breastfeeding is advised to be temporarily discontinued for at least one full elimination half‑life of the drug or its relevant metabolites whenever maternal treatment with magaldrate‑containing combinations is unavoidable.

International breastfeeding guidance notes that simethicone and similar antiflatulents are considered safe for nursing mothers, while general principles emphasize use of the lowest effective dose for the shortest duration and close monitoring of the infant.
Therefore, the lactation risk in A02AF01 combinations is determined primarily by magaldrate and the cumulative aluminum load, and not by the antiflatulent component, which can be regarded as essentially non‑toxic in this context.

In countries where magaldrate–antiflatulent products are not licensed, no direct clinical lactation data on these exact combinations are available, and risk assessment must be extrapolated from the monographs on magaldrate and on aluminum‑ and magnesium‑based antacids in general.
Given the absence of compelling therapeutic advantages over other antacids with more established lactation safety, the use of A02AF01 combinations during breastfeeding is generally discouraged in your categorization system.

Practical recommendations for clinical use in breastfeeding

When a breastfeeding patient requires symptomatic treatment of upper dyspepsia with prominent gas and bloating, non‑aluminum antacids (for example, calcium or magnesium salts without aluminum) or separate administration of a compatible antacid plus simethicone may be preferred over fixed magaldrate‑antiflatulent combinations.
If, despite these considerations, a magaldrate‑antiflatulent product from A02AF01 must be used, treatment should be limited to the shortest possible duration at the lowest effective dose, and alternative feeding options for the infant should be considered during the exposure period and for the time required for maternal drug elimination.

Particular caution is warranted in premature infants, neonates, and those with renal impairment, in whom even small increments in aluminum exposure may be clinically relevant.
Healthcare professionals should counsel mothers about potential risks, document the risk–benefit analysis, and encourage prompt reporting of any changes in the infant’s gastrointestinal function, behavior or growth.

Because no magaldrate–antiflatulent products are currently registered in your national market, prescribers and pharmacists should base their decisions on the detailed toxicological and lactation monographs for magaldrate and for aluminum‑containing compounds published on your platform, and, where available, on up‑to‑date international lactation databases.
This individualized approach is essential because combined preparations require thorough knowledge of the toxicological profile of each component, and the most toxic ingredient usually dictates the overall lactation risk category.